Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263

Fujimoto, D; Yamashita, D; Fukuoka, J; Kitamura, Y; Hosoya, K; Kawachi, H; Sato, Y; Nagata, K; Nakagawa, A; Tachikawa, R; Date, N; Sakanoue, I; Hamakawa, H; Takahashi, Y; Tomii, K

Fujimoto, D (reprint author), Kobe City Med Ctr Gen Hosp, Dept Resp Med, Chuo Ku, 2-1-1 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.

ANTICANCER RESEARCH, 2018; 38 (12): 6891

Abstract

Background/Aim: While the PD-L1 22C3 pharmDx assay is an FDA-approved diagnostic assay for pembrolizumab use, not every pathology laboratory has the D......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索